Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 4Leukemia, Myeloid, Acute 4Leukemia, Myelomonocytic, Chronic 3Leukemia 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 4Azacitidine 3venetoclax 2fludarabine phosphate 2fludarabine 2ON 01910 2Mycophenolic Acid 2Melphalan 2Filgrastim 2Cyclosporine 2Busulfan 2lonafarnib 1itacitinib 1ilorasertib 1exatecan 1darinaparsin 1cedazuridine 1Whole-Body Irradiation 1Transplantation 1Teriparatide 1Radiotherapy 1Piperacillin, Tazobactam Drug Combination 1Peripheral Blood Stem Cell Transplantation 1Parathyroid Hormone 1Methotrexate 1Mesna 1INCB039110 1Granulocyte Colony-Stimulating Factor 1Glycopeptides 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Anemia, Refractory, with Excess of Blasts × cedazuridine × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡